Preclinical evaluation demonstrates a nanoreactor drives dual-route reactions to reverse tumor immunosuppression, indicating a strategy to boost antitumor immunity.
S in tumors for enhanced chemodynamic therapy and complete energy metabolism block through synergistic dual-route reactions, consequently leading to efficient immunogenic cell death and eliciting a robust immune response.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: